Franklin Sedarat, M.D. MSc, Director of Hematopathology, Mark Edinger, Scientific Advisor Flow Cytometry, Patrick Hurban, Ph.D., Senior Director and Global Head of Translational Genomics, Q2 Solutions
Measurement of minimal residual disease (MRD) is one of the best predictors of treatment outcome for leukemia, lymphoma and myeloma. First found to be of great value in monitoring chronic myelogenous leukemia (CML), MRD has become generally useful across other types of leukemia and lymphoma, and has become essential in monitoring, modifying and reinitiating therapeutic intervention. It has also brought about a new definition of remission based on the improved detection and measurement of very low levels of residual malignant cells.
This paper explores, in further detail, the current landscape of MRD detection, key considerations for each approach, and current advancements that will contribute to even further improved MRD detection in the future.